Angiodynamics Inc (ANGO) Stock Price, Quote & News

Company Profile

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy sy...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 518 795 1400

Website: www.angiodynamics.com

Address:

14 Plaza Drive, Latham, United States

alfredaita Jan. 25 at 5:28 PM

$ANGO short interest to float high, significant amount of shares owned by Millennium and Izzy Englander. Seems like an Ethical individual. My guess is they may assist in finding a CEO replacement. Tariff relief would help.

0 · Reply

Estimize Jan. 22 at 11:42 PM

Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c

0 · Reply

SolarWind Jan. 15 at 8:56 PM

$ANGO over $35 in the next two years...

1 · Reply

Estimize Jan. 14 at 11:45 AM

Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c

0 · Reply

SolarWind Jan. 13 at 7:17 PM

$ANGO It's candle stick Hammer Time.

0 · Reply

ZacksResearch Jan. 13 at 7:03 PM

Margin quality is improving in MedTech — and these 3 names are leading it. 📈 $ANGO, $BSX, and $MDT are seeing earnings quality improve as higher-margin products take share, supporting stronger margins and more durable growth across the MedTech space. See why product mix is becoming a key driver for these stocks 👉 https://www.zacks.com/stock/news/2816795/3-medtech-stocks-benefiting-from-favorable-product-mix-shifts?cid=sm-stocktwits-2-2816795-teaser-28741&ADID=SYND_STOCKTWITS_TWEET_2_2816795_TEASER_28741

0 · Reply

alfredaita Jan. 8 at 7:10 PM

$ANGO stock dives on earnings day as Jim Clemens set to retire once replacement found. But this was already known as of 12/23 if not sooner. Strange

0 · Reply

hohumStocks Jan. 8 at 7:05 PM

$ANGO Looks like a discount and value at current level with recent overreaction post positive earnings. I’m in with a big position here! Let’s see what happens.

0 · Reply

SkookBuffett Jan. 8 at 6:45 PM

$ANGO clown world that this is getting slaughtered today

0 · Reply

ZacksResearch Jan. 7 at 7:19 PM

$ANGO's surprising reversal — what's behind yesterday's 13.5% drop? 🤔 🌟 Q2 saw breakeven adjusted EPS, beating a projected adjusted 10-cent loss 📈 Pro-forma revenue hit $79.4M, up 8.8% YoY and above estimates Yet, despite strong financials and no debt, shares tumbled. Understand the full context here 👉 https://www.zacks.com/stock/news/2813636/ango-stock-dips-despite-q2-earnings-beat-gross-margin-improves?cid=sm-stocktwits-2-2813636-body-27892&ADID=SYND_STOCKTWITS_TWEET_2_2813636_BODY_27892

0 · Reply

AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 10:18 AM EST - 21 days ago

AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript

Jan 6, 2026, 6:00 AM EST - 21 days ago

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

Dec 30, 2025, 6:51 AM EST - 4 weeks ago

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Dec 29, 2025, 6:47 PM EST - 4 weeks ago

AngioDynamics: Growth Remains Under The Radar

Dec 23, 2025, 8:00 AM EST - 5 weeks ago

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

Dec 22, 2025, 8:00 AM EST - 5 weeks ago

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 10, 2025, 10:31 AM EST - 2 months ago

AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript

Oct 27, 2025, 4:30 PM EDT - 3 months ago

AngioDynamics to Participate in the UBS Global Healthcare Conference

Oct 13, 2025, 8:30 AM EDT - 3 months ago

AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List

Oct 2, 2025, 3:00 PM EDT - 4 months ago

AngioDynamics: Discounted Sales Multiple With Real Growth Engines

Oct 2, 2025, 10:02 AM EDT - 4 months ago

AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

Oct 2, 2025, 9:44 AM EDT - 4 months ago

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

Oct 2, 2025, 6:00 AM EDT - 4 months ago

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

Oct 1, 2025, 9:57 AM EDT - 4 months ago

Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings

Sep 18, 2025, 8:00 AM EDT - 4 months ago

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

Aug 17, 2025, 8:23 AM EDT - 5 months ago

AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul

Aug 6, 2025, 4:30 PM EDT - 6 months ago

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 28, 2025, 8:30 AM EDT - 6 months ago

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

Jul 23, 2025, 8:30 AM EDT - 6 months ago

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

Jul 15, 2025, 12:40 PM EDT - 7 months ago

AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

Jul 15, 2025, 11:59 AM EDT - 7 months ago

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

Jul 15, 2025, 6:30 AM EDT - 7 months ago

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

Jul 7, 2025, 8:00 AM EDT - 7 months ago

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

Jun 23, 2025, 8:00 AM EDT - 7 months ago

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

Apr 2, 2025, 10:41 AM EDT - 10 months ago

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

Apr 2, 2025, 10:20 AM EDT - 10 months ago

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

Apr 2, 2025, 6:30 AM EDT - 10 months ago

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

Mar 31, 2025, 8:00 AM EDT - 10 months ago

AngioDynamics to Host Virtual Cardiovascular Investor Event

Mar 19, 2025, 8:00 AM EDT - 11 months ago

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

Mar 10, 2025, 4:30 PM EDT - 11 months ago

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

Jan 30, 2025, 7:30 AM EST - 1 year ago

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

Jan 16, 2025, 5:07 AM EST - 1 year ago

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

Jan 13, 2025, 8:00 AM EST - 1 year ago

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

Jan 8, 2025, 5:15 PM EST - 1 year ago

AngioDynamics: A Surgical Approach To Market Growth

Jan 8, 2025, 11:00 AM EST - 1 year ago

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

Jan 8, 2025, 6:30 AM EST - 1 year ago

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

Jan 6, 2025, 9:26 AM EST - 1 year ago

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:25 AM EST - 1 year ago

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

Dec 19, 2024, 5:00 PM EST - 1 year ago

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

Dec 9, 2024, 6:00 AM EST - 1 year ago

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

Oct 23, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

Oct 21, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

Oct 3, 2024, 10:29 AM EDT - 1 year ago

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

Oct 3, 2024, 10:02 AM EDT - 1 year ago

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

LEVI NGVT

Oct 3, 2024, 6:30 AM EDT - 1 year ago

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

Oct 3, 2024, 3:37 AM EDT - 1 year ago

Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings

Sep 19, 2024, 4:40 PM EDT - 1 year ago

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

Sep 19, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

Sep 3, 2024, 8:30 AM EDT - 1 year ago

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

alfredaita Jan. 25 at 5:28 PM

0 · Reply

Estimize Jan. 22 at 11:42 PM

Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c

0 · Reply

SolarWind Jan. 15 at 8:56 PM

$ANGO over $35 in the next two years...

1 · Reply

Estimize Jan. 14 at 11:45 AM

Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c

0 · Reply

SolarWind Jan. 13 at 7:17 PM

$ANGO It's candle stick Hammer Time.

0 · Reply

ZacksResearch Jan. 13 at 7:03 PM

0 · Reply

alfredaita Jan. 8 at 7:10 PM

$ANGO stock dives on earnings day as Jim Clemens set to retire once replacement found. But this was already known as of 12/23 if not sooner. Strange

0 · Reply

hohumStocks Jan. 8 at 7:05 PM

$ANGO Looks like a discount and value at current level with recent overreaction post positive earnings. I’m in with a big position here! Let’s see what happens.

0 · Reply

SkookBuffett Jan. 8 at 6:45 PM

$ANGO clown world that this is getting slaughtered today

0 · Reply

ZacksResearch Jan. 7 at 7:19 PM

0 · Reply

ZacksResearch Jan. 7 at 6:19 PM

ANGO dips after earnings — but the fundamentals quietly improved ⚠️ $ANGO posted a Q2 earnings beat with revenue up 8.8% and gross margin expanding 170 bps, driven by stronger Med Tech performance — yet the stock still sold off. Is the market missing the margin story here? Full breakdown 👉 https://www.zacks.com/stock/news/2813636/ango-stock-dips-despite-q2-earnings-beat-gross-margin-improves?cid=sm-stocktwits-2-2813636-teaser-27866&ADID=SYND_STOCKTWITS_TWEET_2_2813636_TEASER_27866

0 · Reply

BioGem Jan. 7 at 12:16 AM

$ANGO I am buying at this unwarranted discount today: -Beat by a hefty margin the revenue expectations. -Beat Adj EBIDTA and cash flow expectations. -Solid raise in guidance for revenue and bottom line every single quarter. -Much improved gross margins. -All 3 Med Tech products grew nicely. Even the Med devices have a healthy growth now. -Recent insiders buy in the 11$ range. -Significant R&D projects to expand indications. -Big institutional buys through 2025. -High price targets by all analysts. $XBI $IBB

1 · Reply

Bazzzigar Jan. 6 at 11:43 PM

$ANGO below $8?

0 · Reply

StocktwitsEarnings Jan. 6 at 11:01 PM

$ANGO Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.15 down -42.31% YoY • Reported revenue of $79.43M up 9.04% YoY • AngioDynamics raised its full year FY 2026 guidance for net sales to $312-$314 million and Adjusted EBITDA to $8.0-$10.0 million, while maintaining expectations for positive free cash flow.

0 · Reply

DEXWireNews Jan. 6 at 7:51 PM

$ANGO Q2 FY26 results 🔍 • Revenue $79.4M (beat) • Adj EPS $0.00 (beat) • FY26 guidance raised • FDA IDE + 510(k) approvals • Analysts PT: $19.33 (+63%) Stock still fell −14% on CEO transition news. Overreaction or trend break? Full analysis 👇 https://dexwirenews.com/angiodynamics-ango-q2-fiscal-2026-earnings-stock-buy-after-40-percent-rally/

0 · Reply

_BTD8STR Jan. 6 at 5:02 PM

$ANGO beats Q2 expectations & raises FY26 revenue guidance to $314M! 🚀 The Growth Engine: ⚡️ Med Tech revenue +13% ⚡️ NanoKnife +22% ⚡️ Auryon +18% Operational wins and EPS beat!

1 · Reply